Trends in pharmacotherapy for XXXX .

@entity1 @entity295 @entity452 @entity935 @entity1951 @entity600 @entity693 @entity701 @entity299 @entity551
OBJECTIVE: To determine trends in pharmacotherapy for @entity551 in all @entity1 and in @entity600 ( @entity600 , birth weight 300-1000  g) @entity1 . STUDY DESIGN: We queried the Pediatric Health Information System database for all @entity1  <=28  days with a diagnosis code for @entity551 that were discharged between January 2001 and December 2012. @entity1 were excluded if they had complex @entity299 or cardiac surgery, @entity295 or @entity693 , or had extracorporeal membrane oxygenation. We determined trends in pharmacotherapy for @entity551 in all @entity1 and @entity600 @entity1 , an especially vulnerable group. RESULTS: A total of 8019 @entity551 @entity1 met study criteria. The 2 most prescribed medications were @entity935 (65.3%) and @entity452 (19.9%). For 1487 @entity551 @entity600 @entity1 , the 2 most prescribed medications were @entity935 (83.4%) and @entity701 (33%). During the study period, the use of @entity452 decreased, and @entity701 and vasopressin use increased for all @entity1 and for @entity600 @entity1 . CONCLUSIONS: Treatment of @entity551 varies widely between institutions and individual practitioners, and pharmacotherapy for @entity551 has changed over the past decade. Although @entity935 and @entity452 were the most frequently used agents, their use has declined and the uses of @entity701 and @entity1951 have increased.
